Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 2/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | CBX7 | O95931 | 2/20 | 0.34 |
| ▸ | CDYL2 | Q8N8U2 | 2/20 | 0.34 |
| ▸ | CDYL | Q9Y232 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | CDY1; CDY1B | Q9Y6F8 | 1/20 | 0.34 |
| ▸ | GRIN2B | Q13224 | 3/20 | 0.33 |
| ▸ | MAPT | P10636 | 2/20 | 0.33 |
| ▸ | IRAK4 | Q9NWZ3 | 2/20 | 0.32 |
| ▸ | SMO | Q99835 | 1/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.32 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.32 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4877285 | 0.93 | MAPT (0.36) | TP53GAAPOLBTSHRCBX7 | |
| SCHEMBL4876782 | 0.92 | GAA (0.37) | TP53GAAPOLBTSHRCBX7 | |
| SCHEMBL4877463 | 0.91 | GAA (0.36) | TP53GAAPOLBTSHRCBX7 | |
| SCHEMBL4872058 | 0.90 | GAA (0.40) | TP53GAAPOLBTSHRCBX7 | |
| SCHEMBL4878078 | 0.89 | GAA (0.39) | TP53GAAPOLBTSHRCBX7 | |
| SCHEMBL4874410 | 0.89 | TRPV4 (0.38) | GAAPOLBTSHRGRIN2BIRAK4 | |
| SCHEMBL4872438 | 0.89 | TSHR (0.37) | TP53GAAPOLBTSHRCBX7 | |
| SCHEMBL4877158 | 0.88 | PIK3CA (0.40) | TP53GAAPOLBTSHRCBX7 | |
| SCHEMBL4867002 | 0.88 | IRAK4 (0.35) | TP53GAAPOLBTSHRCBX7 | |
| SCHEMBL4875205 | 0.87 | IRAK4 (0.36) | TP53GAAPOLBTSHRCBX7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080051384-A1 | ANTIVIRAL AGENTS | GENELABS TECHNOLOGIES, INC. | 2008-02-28 | — | — | US | disclosed |
| US-20080051384-A1 | ANTIVIRAL AGENTS | GENELABS TECHNOLOGIES, INC. | 2008-02-28 | — | — | US | disclosed |
| US-20080051384-A1 | ANTIVIRAL AGENTS | GENELABS TECHNOLOGIES, INC. | 2008-02-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080051384-A1 | ANTIVIRAL AGENTS | EIF2AK2, MAVS, ZC3HAV1 | TP53 3049/4885GAA 66/4885POLB 327/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.